India's Leading Vitamin D3 Producer Expands Capacity to Tap Booming Nutraceutical and Functional Foods Market; Commercial Production Scheduled for FY28

Fermenta Biotech Ltd., India's only manufacturer of Vitamin D3 and one of the world's three largest producers of the essential nutrient, has announced a significant expansion of its manufacturing capabilities at its Dahej facility in Gujarat. The company is investing ₹110 crore to increase production of plant-based Vitamin D3, Vitamin D3 derivatives and green-chemistry enzymes, strengthening its position in the rapidly growing global nutraceutical industry.

The expansion reflects changing consumer preferences towards vegetarian and vegan nutritional supplements, clean-label ingredients and sustainably sourced products. Commercial production from the new facilities is expected to begin during FY28, enabling Fermenta to cater to rising domestic and international demand while reducing India's dependence on imported plant-based Vitamin D3 ingredients.

The investment also aligns with India's broader manufacturing ambitions by promoting indigenous production of specialised biotechnology products with significant export potential.

Major Capacity Addition Planned at Dahej Plant

Fermenta Biotech's expansion project will substantially increase its production capabilities across multiple high-value product categories.

The company plans to add annual capacity of:

• One tonne of plant-based Vitamin D3

• 50 kilograms of Vitamin D3 derivatives, including calcifediol

• 75 kilolitres of fermentation capacity for green-chemistry enzymes

Managing Director Prashant Nagre said the project is expected to be completed within the next nine to twelve months, with commercial production commencing in FY28.

The expansion follows earlier investments at the Dahej facility, including a 25% increase in Vitamin D3 crystal production capacity completed in 2021.

₹110 Crore Investment to Drive Future Growth

The entire expansion programme represents an investment of approximately ₹110 crore.

The capital expenditure includes:

• Plant-based Vitamin D3 manufacturing

• Vitamin D3 derivative production

• Green chemistry enzyme facilities

• Fermentation infrastructure

• Technology upgrades

• Capacity enhancement

Around ₹60 crore has been specifically allocated for expanding production of plant-based Vitamin D3 and its derivatives.

The project is expected to strengthen Fermenta's presence in premium nutrition ingredients while opening new revenue opportunities in specialised healthcare applications.

Growing Shift Towards Plant-Based Nutrition

The global nutrition industry has witnessed a major shift towards plant-derived ingredients over the past decade.

Consumers are increasingly demanding products that are:

• Vegetarian

• Vegan

• Sustainably produced

• Traceable

• Clean-label

• Environmentally responsible

Traditional Vitamin D3 is typically derived from lanolin, a wax extracted from sheep's wool.

Although widely used, lanolin-derived Vitamin D3 is unsuitable for many vegetarian and vegan consumers.

This has created a rapidly expanding market for plant-based alternatives across dietary supplements, fortified foods and beverages.

VITADEE Green: A Decade of Research

Fermenta's plant-based Vitamin D3 product, marketed as VITADEE Green, represents nearly ten years of research and development.

The company has developed a proprietary manufacturing process that converts an upcycled agricultural by-product into plant-source Vitamin D3.

While Fermenta has not disclosed the exact botanical source for competitive reasons, management says the technology enables:

• Sustainable production

• Commercial-scale manufacturing

• High product consistency

• Better traceability

• Competitive pricing

The innovation provides Indian manufacturers with a domestically produced alternative to imported plant-based Vitamin D3 ingredients.

Reducing Import Dependence

India has historically relied heavily on imported plant-based Vitamin D3.

Manufacturers seeking vegetarian formulations have often faced:

• Higher import costs

• Longer procurement cycles

• Supply-chain uncertainties

• Limited supplier options

In many cases, companies have instead used Vitamin D2, which differs from Vitamin D3 in its biological characteristics and formulation requirements.

Fermenta believes local manufacturing will improve affordability while strengthening India's self-reliance in specialty nutrition ingredients.

Applications Across High-Growth Healthcare Segments

The expanded production capacity will cater to multiple fast-growing industries.

Dietary Supplements

• Tablets

• Capsules

• Gummies

• Softgels

Functional Foods

• Fortified cereals

• Dairy alternatives

• Health snacks

• Nutrition bars

Health Beverages

• Protein drinks

• Nutrition beverages

• Functional juices

• Wellness products

Pharmaceutical Products

• Prescription Vitamin D formulations

• Preventive healthcare products

• Clinical nutrition

The ingredient will be supplied in both powder and oil formats, offering manufacturers greater formulation flexibility.

India's Vitamin D Market Continues to Expand

Fermenta estimates that India's 60,000 IU Vitamin D3 formulation market alone is worth between ₹1,000 crore and ₹1,500 crore.

The broader vitamins and minerals market is estimated at approximately:

₹20,600 crore

Vitamin D consumption has recorded double-digit growth over the past five years.

Although pandemic-related demand has normalised, consumption remains significantly higher than pre-COVID levels due to increasing awareness of preventive healthcare.

Key growth drivers include:

• Rising health consciousness

• Preventive nutrition

• Routine health screening

• Growth of nutraceutical products

• Increasing physician recommendations

Vitamin D Deficiency Remains Widespread

India continues to experience a high prevalence of Vitamin D deficiency despite abundant sunlight.

Several lifestyle and environmental factors contribute to low Vitamin D levels, including:

• Indoor lifestyles

• Limited outdoor exposure

• Air pollution

• Darker skin pigmentation

• Obesity

• Dietary limitations

Vitamin D is essential for:

• Calcium absorption

• Bone health

• Muscle function

• Immune support

Severe deficiency may result in:

Children

• Rickets

• Poor bone development

• Skeletal deformities

Adults

• Osteomalacia

• Bone pain

• Muscle weakness

• Increased fracture risk

Growing awareness of these health issues is expected to sustain long-term demand for supplementation.

Customer Qualification Process Underway

Fermenta has already initiated qualification programmes with potential customers across:

• Nutraceutical manufacturers

• Dietary supplement companies

• Functional food producers

• Beverage manufacturers

However, the company has not yet announced confirmed commercial supply agreements.

Management expects revenue from the expanded capacity to increase progressively after commissioning as customer approvals are completed and production utilisation rises.

Human Nutrition Business Drives Revenue

Human nutrition remains Fermenta's largest business segment.

During FY26:

• Human Nutrition contributed approximately 53% of consolidated revenue.

• Animal Nutrition accounted for around 20%.

The company reported consolidated revenue of approximately ₹551 crore during FY26.

The expansion is expected to further strengthen its nutrition business while diversifying into higher-value speciality ingredients.

Global Nutraceutical Industry Offers Significant Opportunity

The worldwide nutraceutical market continues to benefit from powerful long-term growth trends.

Key themes include:

• Preventive healthcare

• Plant-based nutrition

• Functional foods

• Personalised wellness

• Sustainable ingredients

• Clean-label formulations

• Healthy ageing

Manufacturers increasingly require innovative ingredients capable of meeting evolving consumer expectations regarding health, sustainability and transparency.

Investment Perspective

Fermenta Biotech's latest expansion demonstrates its ambition to move beyond conventional Vitamin D3 production towards premium speciality nutrition ingredients.

Growth Positives

• Entry into high-growth plant-based nutrition.

• Import substitution opportunity.

• Proprietary manufacturing technology.

• Strong demand for clean-label ingredients.

• Diversified application across food and healthcare.

• Expansion into value-added derivatives.

Potential Risks

• Project execution delays.

• Slower customer qualification.

• Capacity utilisation risks.

• Competitive pressure from international suppliers.

• Changes in global nutraceutical demand.

Market Outlook

Fermenta Biotech's investment in plant-based Vitamin D3 production positions the company to benefit from some of the most significant structural trends shaping the global healthcare and nutrition industry. Rising demand for vegetarian supplements, preventive healthcare products and sustainable ingredients is creating new opportunities for manufacturers capable of offering high-quality, locally produced alternatives.

With commercial production expected to begin in FY28, the expanded Dahej facility could strengthen Fermenta's leadership in Vitamin D3 manufacturing while opening new avenues in functional foods, nutraceuticals and pharmaceutical formulations. Although commercial success will depend on customer adoption and capacity utilisation, the company's proprietary technology, strong manufacturing capabilities and focus on innovation place it in a favourable position to capitalise on the long-term growth of India's rapidly evolving nutrition and wellness market.